Tsuzi, D., Maeta, K., Takatsume, Y., Izawa, S
Based on my experience leading clinical trials in obesity and diabetes, these data show the potential for orforglipron to offer an efficacy, safety, and tolerability profile consistent with the injectable GLP-1 class," said Louis J
Your nervous system responds to this blocking action with a chain of effects
The involvement of DPP-4 in metabolism of endogenous SDF-1 is compatible with the finding that the truncated metabolite, SDF-1 3-67, was present in wild-type mice, but not in animals lacking DPP-4 (62), with this observation being extended in subsequent studies in mice and Rhesus monkeys (63) and in patients with T2DM (64) showing that levels of SDF-1 3-67 were reduced while those of the intact 1-67 form increased concomitantly when DPP-4 activity was inhibited
Clinical Trial Outcomes with Monotherapy The REDEFINE 1 trial demonstrated that cagrilintide monotherapy at the 4.5 mg maintenance dose produced mean body weight reductions of approximately 10.8% from baseline after 32 weeks of treatment [4]
